# A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies

> clinical trial · VERIFIED · 2026-06-05

Status: NOT_YET_RECRUITING · Sponsor: The First Affiliated Hospital with Nanjing Medical University · Condition: Relapsed/Refractory B-cell Malignancies

- Company: The First Affiliated Hospital with Nanjing Medical University
- Sector: cell therapy
- Primary source: https://clinicaltrials.gov/study/NCT07628582

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.